A Biomanufacturing Bottleneck Threatens To Blunt Biotech's Boom

A confluence of factors is straining the ability of biomanufacturing facilities to fulfill demand and supply critical capacity for biotech startups.

Related Keywords

North Carolina ,United States ,Alexandria ,Al Iskandariyah ,Egypt ,Texas ,Massachusetts ,Philadelphia ,Pennsylvania ,Colorado ,Boston ,Riverside ,California ,Maryland ,San Diego ,Cambridge ,Cambridgeshire ,United Kingdom ,Morrisville ,Audrey Greenberg ,Pete Briskman ,Matan Cos ,Matt Gardner ,Thomas Obrien ,Devin Gleeson ,Shane Poppen ,Investment Group ,Life Science Economic Development Laura Rowley ,Carolina Biotechnology Center ,Carolina Research Triangle ,Alexandria Real Estate Equities ,Cbre Us Advisory Life Sciences Practice ,Riverside Research Park ,Bioplan Associates ,Suffolk Downs ,Life Sciences ,Current Good Manufacturing Practice ,Real Estate Equities ,Breakthrough Medicines ,Boston Based Homology Medicines ,Construction Vice President Devin Gleeson ,North Carolina Biotechnology Center Director ,Trinity Capital ,Crescent Communities ,Managing Director Pete Briskman ,Greater Boston ,Bay Area ,Research Triangle ,Plan Associates ,Cbre ,Alexandria Real Estate Equities Inc , ,Biomanufacturing ,Boston Life Sciences ,He Hym Group ,Ife Sciences Construction ,